Literature DB >> 31000671

Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary Mycobacterium avium complex disease.

Sanne M H Zweijpfenning1, Jodie A Schildkraut2, Jordy P M Coolen2, Carolien Ruesen2, Ellen Koenraad2, Anne Janssen2, Mike M Ruth2, Arjan S de Jong2, Saskia Kuipers2, Rob E Aarnoutse3, Cecile Magis-Escurra1, Wouter Hoefsloot1, Jakko van Ingen4.   

Abstract

Entities:  

Year:  2019        PMID： 31000671     DOI： 10.1183/13993003.00118-2019

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  4 in total

1.  Efficacy of Bedaquiline, Alone or in Combination with Imipenem, against Mycobacterium abscessus in C3HeB/FeJ Mice.

Authors:  Vincent Le Moigne; Clément Raynaud; Flavie Moreau; Christian Dupont; Jérôme Nigou; Olivier Neyrolles; Laurent Kremer; Jean-Louis Herrmann
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

2.  Successful bedaquiline-containing antimycobacterial treatment in post-traumatic skin and soft-tissue infection by Mycobacterium fortuitum complex: a case report.

Authors:  Johanna Erber; Simon Weidlich; Tristan Tschaikowsky; Kathrin Rothe; Roland M Schmid; Jochen Schneider; Christoph D Spinner
Journal:  BMC Infect Dis       Date:  2020-05-24       Impact factor: 3.090

Review 3.  Recent advances in nontuberculous mycobacterial lung infections.

Authors:  David Horne; Shawn Skerrett
Journal:  F1000Res       Date:  2019-10-01

4.  In vitro assessment of 17 antimicrobial agents against clinical Mycobacterium avium complex isolates.

Authors:  Siran Lin; Wenya Hua; Shiyong Wang; Yu Zhang; Xinchang Chen; Hong Liu; Lingyun Shao; Jiazhen Chen; Wenhong Zhang
Journal:  BMC Microbiol       Date:  2022-07-08       Impact factor: 4.465
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.